Drug Conjuagate Advances for Poor-Prognosis NSCLC

(MedPage Today) -- Good results in small study of trastuzumab linked to antimicrotubule agent
Source: MedPage Today Pulmonary - Category: Respiratory Medicine Source Type: news

Related Links:

CONCLUSIONS The results of this research indicate that the metastases of non-small cell lung cancer can predict RET rearrangement of the primary tumor tissue in the majority of cases. Testing for RET rearrangement in metastases can be used as an alternative to testing of primary tumor tissue if it is inaccessible. PMID: 30429449 [PubMed - in process]
Source: Medical Science Monitor - Category: Research Tags: Med Sci Monit Source Type: research
Non-small cell lung cancer (NSCLC) represents more than about 80% of the lung cancer. The early stages of NSCLC can be treated with complete resection with a good prognosis. However, most cases are detected at...
Source: BMC Medical Genomics - Category: Genetics & Stem Cells Authors: Tags: Research Source Type: research
AbstractSeveral cancers, especially non-small cell lung cancer (NSCLC), are able to escape the immunosurveillance of tumor-infiltrating lymphocytes (TILs); among the molecules involved, the indoleamine 2,3-dioxygenase 1 (IDO-1) and the programmed cell death ligand-1 (PD-L1) play a crucial role. These aspects are of great interest in the current immunotherapeutic era, therefore the current study analyses the TILs, IDO-1, and PD-L1 interactions and their correlations with clinicopathological parameters and prognosis in NSCLC. One hundred ninety-three NSCLC surgical specimens, formalin-fixed, and paraffin-embedded were assess...
Source: Virchows Archiv - Category: Pathology Source Type: research
AbstractNon-small cell lung cancer (NSCLC) accounts for up to 85% of all lung cancers. The last few years have seen the development of a new staging system, diagnostic procedures such as liquid biopsy, treatments like immunotherapy, as well as deeper molecular knowledge; so, more options can be offered to patients with driver mutations. Groups with specific treatments account for around 25% and demonstrate significant increases in overall survival, and in some subgroups, it is important to evaluate each treatment alternative in accordance with scientific evidence, and even more so with immunotherapy. New treatments similar...
Source: Clinical and Translational Oncology - Category: Cancer & Oncology Source Type: research
In this study, we provide the expression pattern of LYPLA1 in non‑small cell lung cancer (NSCLC) using four different NSCLC cell lines. Western blot analysis and RT‑PCR were performed to detect the protein expression and mRNA expression of LYPLA1 in NSCLC cell lines. We detected the highest LYPLA1 protein expression level in SPC‑A‑1 cells followed by A549 cells, and the highest LYPLA1 mRNA expression level was detected in the SPC‑A‑1 cells followed by the H1299 cell line. We found that suppression of LYPLA1 expression using small‑interfering RNA significantly inhibited proliferation, migration and invasion of...
Source: Oncology Reports - Category: Cancer & Oncology Tags: Oncol Rep Source Type: research
This study assessed the possible mechanism of Oenothein B on lung cancer A549 cell. The results showed that Oenothein B effectively inhibited the proliferation of A549 cells by inducing apoptosis, arrested cell at G1 stage. On the one hand, Oenothein B not only increased the level of intracellular reactive oxygen species (ROS), but induced some apoptotic-related protein expression (cleavage caspase-3, PARP, cytochrome c level in the cytoso, Bax). Moreover, ROS inhibitor and PI3K agonist exhibited significant protection against cell death by Oenothein B. ROS inhibitor significantly abrogated the activation of caspase3/7...
Source: Chemico Biological Interactions - Category: Biochemistry Source Type: research
CONCLUSIONS: An increase in CGP utilization from 2% to 10% among patients with advanced NSCLC undergoing molecular diagnostic testing was associated with modest budget impact, most of which was attributable to increased use of more effective treatments and prolonged survival. PMID: 30430885 [PubMed - as supplied by publisher]
Source: Journal of Medical Economics - Category: Health Management Tags: J Med Econ Source Type: research
Conditions:   Non Small Cell Lung Cancer;   EGFR Gene Mutation Exon 20;   HER2 Gene Mutation Intervention:   Drug: Tarloxotinib Sponsor:   Rain Therapeutics, inc Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   NSCLC;   Breast Cancer Intervention:   Drug: Poziotinib Sponsor:   Spectrum Pharmaceuticals, Inc Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Authors: Li Q, Ma W, Li T PMID: 30430029 [PubMed]
Source: Journal of Thoracic Disease - Category: Respiratory Medicine Tags: J Thorac Dis Source Type: research
More News: Herceptin | Non-Small Cell Lung Cancer | Respiratory Medicine | Study